… Targeted therapies licensed to treat gastric cancer include trastuzumab (HER2-positive
patients first line), ramucirumab (anti-angiogenic second line), and nivolumab or pembrolizumab …

… have been/are in targeted therapy clinical trials and, which as … Some gastric cancer biomarkers
that may help in defining … therapies may improve gastric cancer patients’ outcome, but are …

… In summary, acceptable first-line CT for advanced HER2-negative gastric cancer are
combinations of fluoropyrimidine with platinum salt or irinotecan, and triplet combinations of …

… with gastric cancer is also a risk factor. There are several known inherited cancer syndromes
that are associated with gastric cancer. … is found in hereditary diffuse gastric cancer (CDH1) …

… Surgery remains the only curative therapy, while … improve outcome of resectable gastric
cancer with extended lymph node dissection. More than half of radically resected gastric cancer …

… Here we review the evidence supporting current approaches to resectable gastric cancer,
including discussion of the optimal extent of surgery and lymphadenectomy, adjuvant …

… Since the 1970s, gastric cancer therapy has steadily improved with chemotherapeutic
regimens administered in either doublet or triplet combinations. A timeline of recent treatment …

… the vast heterogeneity of gastric cancer by … gastric cancer subtypes share similarity to gastric
cancer as a whole which can be explained by the increase in this subtype of gastric cancer …

… been validated for use in those with gastric cancer. In this review, we … in gastric cancer.
More importantly, the impact of surgery for treatment, palliation and prophylaxis of gastric cancer …

… Molecular classification based on HER2 (also known as ERBB2) status was introduced for
gastric cancers because of therapeutic implications. HER2, which is a member of the human …